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Abstract
 .The high basal level of prolactin PRL gene expression in rat pituitary GH cells is maintained through the spontaneous3
 .activity of voltage-sensitive calcium channels VSCCs . This can be observed experimentally by addition of 0.5 mM CaCl2
to GH cells cultured in a low calcium, serum-free medium. CaCl specifically induces PRL gene expression and this3 2
induction is inhibited by VSCC blockers. PRL gene expression is also stimulated by several hormones and growth factors.
In the present study, we examined the effects of tyrosine kinase inhibitors on the ability of CaCl , basic fibroblast growth2
 .  .  .factor bFGF , epidermal growth factor EGF and thryrotropin-releasing hormone TRH to increase PRL mRNA levels. Of
several PTK inhibitors used, one PTK inhibitor, herbimycin A, specifically inhibited the CaCl -induced increase in2
 .cytoplasmic and nuclear prolactin PRL mRNA without affecting cell viability, cell-cell and cell-matrix adhesion, or the
expression of several other genes. The effects of herbimycin A were reversible. In cells pretreated with herbimycin A, PRL
 .mRNA levels were reduced by 69"12% P-0.001; ns4 .Western blot analysis using anti-phosphotyrosine antibody
 .revealed a decrease of 91"1% P-0.001; ns4 in the phosphotyrosine content of proteins in the molecular weight
range of 130–160 kDa. After changing the medium back to SFM plus 0.5 mM CaCl , levels of PRL mRNA increased over2
a period of several hours, and this increase was accompanied by the tyrosine phosphorylation of two or more proteins in the
approximate size range of 130–160 kDa. Herbimycin A also inhibited PRL gene expression in the independently-derived
 .235-1 lactotrope cell line and lowered the tyrosine specific phosphorylation of protein s in a similar size range. Herbimycin
A inhibited the ability of bFGF, EGF and TRH to stimulate PRL gene expression in GH cells. Again, in cells pretreated3
with herbimycin A, bFGF induced a reappearance of tyrosine-specific phosphorylation, followed by a reappearance of PRL
mRNA. These findings provide evidence for a role for at least one PTK which is necessary for basal and stimulated PRL
gene expression. q 1997 Elsevier Science B.V.
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1. Introduction
Extracellular CaCl can maintain a high basal2
level of PRL gene expression in primary rat pituitary
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cultures and pituitary tumor GH cells in the absence3
w xof serum, growth factors and hormones 1,2 . Culture
of GH cells in a calcium-free, serum-free medium3
 .  .SFM results in a low level of prolactin PRL and
 .growth hormone GH gene expression. Subsequent
addition of 0.5 mM CaCl induces a large 5- to2
.10-fold and specific increase in PRL mRNA levels
0167-4889r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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w x1–3 . Pharmacological studies have implicated L-
2q  .type voltage-sensitive Ca channels VSCCs and
w xcalmodulin in this response 4–7 , whereas protein
w xkinase C does not appear to be involved 8,9 .
Studies on other cell types have established a
 .relationship between protein tyrosine kinases PTKs
and the regulation by extracellular CaCl of a cellular2
response. For example, the induction of mouse kera-
tinocyte differentiation by calcium requires activation
of the nonreceptor PTK, fyn, and at least one other
w xPTK 10 . In neuronal PC12 cells, the VSCC agonist,
BAY K8644, activates MAP kinase via a Ras-depen-
w xdent pathway 11 . The present study was undertaken
to investigate whether PTKs were required for the
maintenance of PRL gene expression by extracellular
CaCl in two independently-derived pituitary tumor2
cell lines. We report here that the PTK inhibitor,
herbimycin A, specifically and reversibly represses
CaCl -supported PRL gene expression in GH3 and2
235-1 cells. Herbimycin A also specifically blocked
the ability of bFGF, EGF and TRH to increase PRL
gene expression. These studies provide evidence for
at least one PTK which is necessary for basal and
stimulated PRL gene expression.
2. Materials and methods
The cloned probes for PRL, GH, and glucose-regu-
 .lated protein 78 GRP78 were described previously
w x2,3 . The glyceraldehyde phosphate dehydrogenase
 . w xGAPDH cDNA clone 12 was provided by Dr.
David Rowe University of Connecticut Health Cen-
.ter, Farmington, CT . GH cells were purchased from3
 .American Type Culture Collection Rockville, MD
and maintained in suspension culture as described
w x13 . The 235-1 cell line was generously donated by
Dr. H.H. Samuels NYU Medical Center, New York,
.NY and was maintained in monolayer as described
w x14 . At the time of an experiment, cells were cen-
trifuged out of growth medium and resuspended in
 .serum-free medium SFM . Although SFM has no
added CaCl , it contains about 50 mM of contaminat-2
ing CaCl . Culturing cells in SFM does not drasti-2
cally lower intracellular Ca2q, but does allow one to
observe the effects of the VSCC on PRL gene ex-
pression by adding 0.5 mM CaCl . GH cells cul-2 3
tured in SFM show greater than 90% viability for
several days, and respond to stimulators of either
w xPRL or GH gene expression 2,13 . The exact treat-
ment for each experiment is described in the legend
to the corresponding figure. Herbimycin A, laven-
dustin A, and methyl-2,5 dihyroxycinnamate were
purchased from Life Technologies Gaithersburg,
.MD , and were diluted in PBS from a DMSO stock
solution. Genistein, daidzein, and RG-13022 were
 .obtained from BIOMOL Plymouth Meeting, PA .
Basic FGF, EGF and TRH were obtained from Sigma
 .St. Louis, MO .
2.1. Analysis of mRNA le˝els by Northern blot hy-
bridization
Preparation of cytoplasmic mRNA for analysis by
either Northern blot or RNA dot hybridization was
w xperformed as described 15 except that the spin step
with vanadyl-ribonucleoside complexes was omitted.
For the preparation of nuclear RNA, GH3 cells were
collected, pooled, washed once in PBS, and then
resuspended in 0.9 ml of PBS. Cells were lysed by
addition of 0.5% NP40, incubated on ice for 3 min,
then centrifuged at 1000=g for 5 min at 48C. The
nuclear RNA was isolated by guanidine extraction
w xand centrifugation through CsCl 14 . The relative
levels of specific mRNAs were measured by North-
ern blot hybridization using 1% agaroserformal-
w xdehyde gels as described 3 . Gels were stained prior
to transfer with ethidium bromide in order to measure
relative mobilities of 28 s and 18 s ribosomal RNAs,
and to ascertain even loading. The DNA probes were
labeled with 32P-dCTP using the Nick-Translation
 .Kit N5000 Amersham, Arlingtin Heights, IL or by
the RTS RadPrime DNA labeling system Life Tech-
.nologies, Gaithersburg, MD , followed by purifica-
tion using MicroSpin S-200 HR columns Pharmacia,
.Piscataway, NJ .
2.2. Western blot analysis of phosphotyrosyl-contain-
ing proteins
For phosphotyrosine immunoblotting, samples
were electrophoresed on either 8% or 10% SDS-poly-
acrylamide gels as indicated. For analysis of whole
cells, the medium was removed and the cells plated
.at equal densities for each treatment were dissolved
by scraping with a Teflon policeman in 250 ml of
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w xboiling Laemmli sample buffer 16 . The samples
were then boiled for 5 min and the DNA was sheared
by passing 5 times through a 26 gauge needle. Insolu-
ble material was removed by centrifuging the cell
lysates for 5 min in a microcentrifuge at 10 000=g.
Prior to electrophoresis, cell extracts were diluted and
the protein concentration of each sample was deter-
w xmined 17 . Typically, 100 mg of protein was elec-
trophoresed. Nitrocellulose sheets were blocked with
10% bovine serum albumin BSA, Boehringer
.Mannheim, Indianapolis, IN in Tris-buffered saline
 .100 mM NaCl, 50 mM Tris-HCl, pH 7.6 containing
0.1% Tween-20 overnight with agitation at room
temperature. After removal of blocking solution, an-
tiphosphotyrosine antibody Upstate Biotechcnology,
.Lake Placid, NY at a dilution of 1:1000 in TBS
containing 3% BSA was added and the blots were
incubated at room temperature with agitation for 1 to
2 h. Horseradish peroxidase conjugated sheep anti-
mouse antibody Kirkegaard and Perry, Inc.,
.Gaithersburg, MD was used at a dilution of 1:25 000
as a secondary antibody and reactivity was deter-
 .mined by chemiluminescence Kirkegaard and Perry
according to manufacturers instructions.
2.3. Quantification of autoradiograms and statistical
analysis
Autoradiograms were scanned with an Apple One
Scanner using Ofoto scanning software Apple Com-
.puters, Cupertino, CA and quantified using IP Lab
 .Gel software Signal Analytics Corp., Vienna, VA .
Alternatively, blots were analyzed by a Betascope
 .blot anaylzer Betagen or by phosphoimaging utiliz-
ing a Phosphoimager SI Molecular Dynamics, Sun-
.nyvale, CA and IP Lab Gel software. The effects of
herbimycin A on RNA levels or phosphotyrosine
content were analyzed by Student’s t test.
3. Results
3.1. Herbimycin A specifically blocked the ability of
extracellular CaCl to maintain high PRL mRNA2
le˝els in somatolactotrope GH cells3
We first screened the effects of several PTK in-
hibitors on the ability of 0.5 mM CaCl to return2
PRL gene expression to a high basal level in GH 3
cells cultured in SFM. The following inhibitors were
examined: genistein, lavendustin A, erbstatin ana-
logue, the tyrophostin RG-13022 and herbimycin A.
Genistein and herbimycin A reduced PRL mRNA
 .levels by approximately 80% Fig. 1 . Lavendustin A
and erbstatin analogue also decreased PRL mRNA to
a lesser extent than genistein and herbimycin A.
RG-13022 had no effect. The inhibitory effects on
PRL mRNA levels of lavendustin A and erbsatin
analogue, and to a lesser extent genistein, were ac-
companied by a noticable decrease in cell viability, as
well as cell-cell and cell-matrix adhesion data not
.shown . In contrast, herbimycin A strongly and re-
producibly inhibited PRL gene expression, but had
little or no effect on the expression of several other
genes, including growth hormone. Also, in at least 10
Fig. 1. Effects of various PTK inhibitors on the ability of CaCl2
to increase PRL mRNA levels in GH cells in 24 h. The3
concentration of each inhibitor utilized was as follows: RG-13022
 .  .  .40 mM , genistein 27.6 mM , daidzein 27.6 mM , herbimycin
 .  .A 875 nM , lavendustin A 25 mM , and erbstatin analogue
 .12.5 mM . Note that erbstatin analogue refers to methyl 2,5-di-
hydroxycinnamate. PRL and GH mRNA levels were measured by
Northern blot or RNA dot hybridization. The percentage values
presented for each inhibitor tested were calculated from the mean
of duplicate samples relative to CaCl -treated controls set at2
.100% from one representative experiment. Variation between
duplicates was less than 5%, except for RG-13022 values, which
varied by 20%.
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experiments, herbimycin A had no visible effect on
cell viability or general appearance, calcium-induced
cell-cell adhesion or adhesion of cells to the tissue
 .culture dish data not shown . Therefore, herbimycin
A was used exclusively for completion of this study.
In a representative experiment shown in Fig. 2A,
treatment of GH cells with CaCl increased PRL by3 2
Fig. 2. Herbimycin A inhibits the CaCl -dependent stimulation of2
 .PRL mRNA levels. A Cytoplasmic PRL and GH mRNA levels
from GH cells that were cultured in SFM in the absence and3
presence of increasing doses of herbimycin A overnight followed
 .by the addition of 0.5 mM CaCl for 24 h. B Nuclear PRL2
RNA. GH cells were cultured in duplicate in SFM in the3
absence and presence of 0.25 mgrml of herbimycin A overnight
followed by the addition of 0.5 mM CaCl for 24 h. The upper2
 .panel of B represents a 1 wk exposure by autoradiography and
 .the lower panel of B represents a 1-h exposure on a Betascope
 .blot analyzer of the area of the blot shown in A depicted by the
arrow. Arrowheads, 28S and 18S rRNA bands. Arrow, fully-
spliced 1 kb-sized PRL mRNA.
Fig. 3. Effect of herbimycin A on PRL mRNA levels in cells
preinduced with CaCl . GH cells were cultured for 24 h in SFM2 3
 .in the absence SFM control or presence of 0.5 mM CaCl .2
 .Herbimycin A 0.5 mgrml was then added for 2.5, 5 and 10 h.
PRL mRNA was assayed in duplicate samples by Northern blot
hybridization and quantified as described in Section 2. Data are
presented as the means of values from duplicate cultures. There
was less than 10% variation between duplicates.
about 5-fold over SFM controls. Herbimycin A at a
concentration of 0.5 mgrml completely blocked the
effect of CaCl , reducing PRL mRNA levels to 14%2
of the CaCl -induced levels. CaCl also induced a2 2
 .small i.e., 1.5- to 2-fold increase in GH mRNA.
Herbimycin A had no effect on these slightly ele-
 .vated GH mRNA levels Fig. 1A . In four separate
 .experiments each performed with duplicate cultures ,
 .herbimycin A significantly P-0.001 reduced PRL
mRNA levels by 69"12%, but did not affect levels
of GAPDH mRNA or GRP78 mRNA data not
.shown . Herbimycin A reduced both cytoplasmic PRL
 .mRNA Fig. 2A and nuclear PRL gene transcripts
 .Fig. 2B .
Previous studies with herbimycin A indicate that
the drug acts by promoting the degradation of spe-
w xcific PTKs 18 . In the experiment shown in Fig. 3,
we examined the relative rapidity of the effect of
herbimycin A in GH cells that had been pretreated3
overnight in SFM plus 0.5 mM CaCl . CaCl in-2 2
creased PRL mRNA about 3-fold over SFM control.
Consistent with previous studies which indicate a
 .relatively slow effect of the drug 18 , herbimycin A
had essentially no effect after 2.5 h, but depressed
PRL mRNA levels by about 50% at 5 h and 10 h.
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3.2. Effects of herbimycin A on the tyrosine-specific
phosphorylation of GH cell proteins and PRL gene3
expression are re˝ersible
The effects of herbimycin A on protein tyrosine
phosphorylation were examined by Western blot
analysis using an anti-phosphotyrosine antibody. In
cells treated overnight with herbimycin A, PRL
mRNA levels were undetectable and a low level of
apparent phosphotyrosine staining was observed on
 .Western blots Fig. 4A . This staining was nonspe-
cific, as it was detected in the absence of primary
 .antibody data not shown . Subsequent to changing
the medium back to SFM containing 0.5 mM CaCl ,2
PRL mRNA levels slowly increased over a 24 h
 .period Fig. 4A, upper panel . Concomitantly, an
increased phosphotyrosine staining of two or more
proteins in the range of approximately 130–160 kDa
 .was detected Fig. 4A, lower panel . The phospho-
tyrosine staining of these proteins was not observed
 .in the absence of primary antibody data not shown ,
nor was it detected in cells that were continually
 .cultured in herbimycin A Fig. 4B or in herbimycin
A-pretreated cells switched to SFM without CaCl2
 .for 24 h lane 1, Fig. 4A .
3.3. Effects of herbimycin A on PRL expression and
tyrosine phosphorylation in 235-1 lactotropes
The 235-1 cell line was independently derived
w xfrom GH cells, and only produces PRL 19 . PRL3
expression is also inducible by CaCl in these cells2
w x14 . Thus, we examined both the effects of her-
bimycin A on the CaCl induction of PRL and on2
tyrosine-specific phosphorylation in this lactotrope
cell line. The profile of tyrosine-specific protein
Fig. 4. A. Effects of Herbimycin A on PRL mRNA levels and
protein tyrosine phosphorylation are reversible by CaCl .. GH2 3
cells cultured in SFM were treated with 0.5 mgrml of her-
bimycin A for 16 h. After medium change, the cells were allowed
to recover in fresh SFM for 5 h, and then incubated for 24 h in
 .  .SFM only -CaCl , or in SFM plus 0.5 mM CaCl qCaCl2 2 2
for 1 h, 9 h, or 24 h. Upper panel, duplicate RNA samples were
probed for PRL mRNA by Northern blot hybridization. RNA
values increased by at least 10-fold between the 1 and 9 h time
points, although exact quantification of this increase is difficult
due to the barely detectable signal in the 1 h sample. Lower
 .panel, antiphosphotyrosine immunoblot 8% polyacrylamide gel .
MW standards are indicated and bracket represents 130-160 kDa
complex. Essentially all of the lighter bands represent nonspecific
staining that was observed in the absence of primary antibody.
Quantification of the lower band within the bracket revealed an
8-fold increase between 24 h samples in the presence and ab-
sence of CaCl . This experiment was repeated twice with similar2
results. B. Effect of continuous treatment of herbimycin A on
tyrosine phosphorylation of GH cell proteins in the 130–1603
kDal size range. Cells were cultured for 16 h in SFM in the
absence or presence of 0.5 mgrml of herbimycin A. CaCl was2
then added to all dishes and cells incubated for an additional 24
h. Tyrosine-specific phosphorylation was examined by Western
blot using a 10% polyacrylamide-SDS gel. Data from four inde-
pendent experiments indicated that the phosphotyrosine content
of the proteins within the size range indicated by the bracket
 .decreased by 91"1% P -0.001 .
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Fig. 5. Effects of herbimycin A on tyrosine-specific phosphoryla-
 . tion upper panel and PRL mRNA levels lower panel, as
.detected by Betagen Betascope in 235-1 lactotropes. MW stan-
 .  .dards are indicated and brackets in A and upper panel of B
denote 150-180 kDa complex. Phosphotyrosine content was re-
duced by about 90%, whereas PRL mRNA was reduced by about
65%. Duplicate values differed by less than 10%.
phosphorylation was very similar between GH and3
 .235-1 cells compare Fig. 4 to Fig. 5 , in that one or
more proteins in the molecular weight range of 130–
160 kDa were strongly stained with anti-phospho-
tyrosine antibody. Both tyrosine phosphorylation and
the level of PRL mRNA in 235-1 cells were de-
 .creased by herbimycin A treatment Fig. 5 .
3.4. Effects of herbimycin A on bFGF, EGF and TRH
stimulation of PRL gene expression
The studies described above show that herbimycin
A effectively inhibits the high basal level of PRL
gene expression, as maintained by extracellular
CaCl , in the absence of serum. PRL gene expression2
is also regulated by numerous growth factors and
hormones. We examined whether herbimycin A
blocked three stimulators of PRL gene expression:
bFGF, EGF and TRH. As shown in Fig. 6, her-
bimycin A essentially completely blocked the effects
of TRH and EGF, and inhibited the effects of FGF by
about 60%.
We next examined whether the effects of her-
bimycin A could be reversed by bFGF after removal
of the drug, similar to the experiment shown in Fig.
4. Again, pretreatment with herbimycin A resulted in
loss of detection of both PRL mRNA Fig. 7, upper
. panel and tyrosine-specific phosphorylation Fig. 7,
.lower panel . Removal of the drug alone did not
 .reverse these observations Fig. 7; lane 1 . However,
addition of bFGF after removal of herbimycin A
induced tyrosine phosphorylation by 6.5 h, and in-
creased PRL mRNA by 12 h. The finding that both
CaCl and bFGF required several hours to increase2
tyrosine phosphorylation is consistent with previous
reports that herbimycin A acts by inducing degrada-
Fig. 6. Herbimycin A inhibits the ability of TRH, EGF and FGF to increase PRL mRNA levels. Cells were treated essentially the same as
 .  .  .described in Fig. 2, except that cells were induced with either TRH 100 nM , EGF 40 ngrml or bFGF FGF; 40 ngrml plus or minus
0.5 mgrml of herbimycin A. Note that FGF was examined in a separate experiment, and is shown with its own SFM control. This was
repeated twice with the same results.
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Fig. 7. The effects of herbimycin A are reversible by bFGF. This
experiment was performed essentially as described in Fig. 4,
except that cells were treated after herbimycin A with 40 ngrml
 .of bFGF FGF . Note that, as indicated, shorter time points were
used for Western blot analysis than those used for Northern blot
analysis.
w xtion of PTKs 18 . We note that in GH cells not3
pretreated with herbimycin A, CaCl and bFGF in-2
duce changes in tyrosine phosphorylation patterns
w x .within minutes 20 , and data not shown .
4. Discussion
Herbimycin A is a benzoquinonoid ansamycin an-
tibiotic that reverses the morphology of various cells
transformed by oncogenic PTKs e.g., Src, Yes, Fps,
.Ros, Abl, Ret, and Erb B but not by oncogenes
which do not posssess PTK activity e.g., Myc, Raf
w x.and Ras; 21,22 . Herbimycin A specifically reduces
the PTK activity of these oncogene products and
thereby lowers the extent of tyrosine phosphorylation
w xof cellular proteins 22 . Herbimycin A also alters the
w xdifferentiated phenotype of various cells 22 . In the
human chronic myelogenous leukemia K562 cell line
expressing a mutated c-Abl with enhanced PTK ac-
tivity, herbimycin A induced erythroid differentiation
concomitant with a reduced tyrosine phosphorylation
w xof the c-Abl kinase 23 . Herbimycin A is also capa-
ble of triggering endoderm differentiation in embry-
onal carcinoma F9 cells, and terminal erythroid dif-
w xferentiation of erythroleukemic MEL cells 24 . Given
the above findings, it is not surprising that her-
bimycin A modulates specific gene expression. The
drug increased fibronectin mRNA levels in RSV-in-
w xfected rat kidney cells 25 , and inhibited c-myc
expression in mouse lymphoblastoma L5178Y cells
w x26 .
In this study, we examined whether several PTK
inhibitors could block the ability of CaCl to induce2
PRL gene expression. Most of these inhibitors re-
duced PRL mRNA nonspecifically andror severly
decreased cell viability. Thus, it is likely that these
drugs inhibited one or more PTKs which are essential
for cell viability. On the other hand, herbimycin A
effectively inhibited the CaCl -induced increase in2
the levels of cytoplasmic PRL mRNA and nuclear
PRL pre-mRNAs. Importantly, this effect of her-
bimycin A was highly specific for PRL, and was
observed in two independently-derived pituitary tu-
mor cell lines. Herbimycin A had no effect on cell
viability or adhesion, and was completely reversible.
Although herbimycin A has been shown to inhibit
several PTKs, the specificity of its effects in GH 3
cells argues that, in this cell type, herbimycin A
 .inhibits one or a few PTK s that are specifically
linked to PRL gene expression. We detected the
presence of one or more proteins in the range of
130–160 kDa whose tyrosine-specific phosphoryla-
tion is inhibited by herbimycin A. This effect of
herbimycin A can be reversed by both CaCl and2
bFGF in a manner that is closely correlated with the
reprise of PRL gene expression. These data support
the assumption that herbimycin A elicits its effects on
PRL gene expression in GH cells through inhibition3
 .of one or more PTK s . However, we have neither
determined the identity of the phosphorylated pro-
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teins, nor any role of these proteins in the regulation
of PRL gene expresson.
The finding that the reversal of herbimycin A-in-
duced effects took several hours is consistent with the
drugs ability to induce selective degradation of some
 w x.of its targets e.g., lck 18 . Also, the finding that
either CaCl or bFGF was required for this reversal2
indicates that these stimulators of PRL gene expres-
sion may also promote the synthesis of a specific
PTK, possibly as part of their ability to induce or
maintain a lactotropic phenotype. In this light, it is
interesting to note that the expression of other PTK
genes is stimulated over a period of 24–48 h upon
hormonal or growth factor induction of differentia-
 w x.tion in other cell types e.g. 27 . Also, it is worth
noting that factors which acutely stimulate PRL gene
 .expression e.g., FGF, EGF, NGF have also been
shown to induce other features of the lactotrope
w xphenotype over a peroid of several days 28–30 ; our
.unpublished observations . Thus, one explanation for
the ability of herbimycin A to block several stimula-
tory factors is that GH cells may express a PTK3
which plays a role in the maintenance of PRL gene
expression as part of the differentiated function of
these cells. Such a PTK could be required for PRL
gene expression, but not necessarily be a component
of the signal transduction pathways of CaCl , FGF,2
EGF and TRH.
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